Moderna’s Lofty Aims To Prevent Diseases With Pandemic Potential

Plans Vaccines For 15 'Priority Pathogens'

The biotech has 15 pathogens in its sights and is also launching mRNA Access that will grant researchers the opportunity to use Moderna's technology platform to develop vaccines for emerging or neglected infectious diseases.

• Source: Archive

Hoping to repeat the success of its mRNA-based COVID-vaccine, Moderna, Inc. has unveiled plans to advance a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases into clinical studies by 2025.

The biotech will target the "15 priority pathogens" deemed by the World Health Organization (WHO) and the Coalition for Epidemic...

More from Anti-infective

More from Therapy Areas